Gilead Sciences Inc. said Thursday that the latest clinical trial evaluating the antiviral medication Hepcludex for the treatment of chronic hepatitis delta virus showed significant viral declines at 48 weeks.
The company said the study's findings underscore the efficacy and safety of Hepcludex, the brand name for the first-in-class entry inhibitor bulevirtide, for treating chronic HDV.
At week 48, study participants treated with bulevirtide monotherapy achieved a greater combined virological and biochemical response than those that weren't treated with bulevirtide.
The data demonstrates a positive impact of bulevirtide on patient-reported outcomes and reinforces the clinical utility of bulevirtide as a monotherapy for chronic HDV, which currently has no other approved treatment options, Gilead said.
The safety profile of the medication at week 48 was consistent with prior reports, with no participants having an adverse reaction that led to discontinuation of the treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.